Browse Full Research Report @
https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market
KS can cause serious problems or even become life treating when the lesions are in the lungs, liver,
or in digestive tract. The means that the when KS occurs in someone is infected with HIV.
Chemotherapy, immunotherapy, and antiretroviral therapy (HAART) are the key treatment methods
for Kaposi sarcoma. The HAART therapy emerged as the leading segment owing to the high
incidence of AIDS-related Kaposi sarcoma globally. HAART therapy includes the combination of
reverse transcriptase (RT) inhibitors, fusion inhibitors, and protease inhibitors. Chemotherapy is
likely to grow at the fastest pace during the forecast period due to the high cost of the treatment
and the increasing adoption by immunocompentent patients.
The leading chemotherapy drugs include paclitaxel, liposomal doxorubicin and daunorubicin,
bleomicin and vincristine. Immunotherapy consists of interferon alfa; which is the first biological
drug approved by the FDA to the treatment of Kaposi sarcoma. Patients with good immune
functions show effectiveness. However, immune compromised patients rarely respond to this
therapy. The therapy accounted for the least share in the global market. Kaposi Sarcoma Market by
Type of Treatment is segmented into Chemotherapy, Liposomal Anthracyclines, Alkaloids,
Immunotherapy, HAART. Kaposi Sarcoma Market by Distribution Channel is segmented into
Hospitals, Cancer Research Institutes, Multispecialty Clinics, Ambulatory Surgical Centers.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market/request-sample
Kaposi Sarcoma Market by Geographical Region is segmented into North America, Latin America,
Europe, Asia-Pacific, and the Middle East and Africa. North America contributed to the major share
in the Kaposi sarcoma market in 2015. Due to the presence of key market players and the increasing
cost of drugs; the growth of the market is also driven by the easy availability of drugs and a high
diagnosis rate of the malignancy. The high cost of the therapy is a deterrent to patients in
developing regions such as Asia Pacific and the Middle East and Africa and this limits its adoption. A
limited number of approved biologics is also a prominent factor restraining the growth of the
immunotherapy segment. The Middle East and Africa are expected to expand at the highest CAGR
during the forecast period owing to the high incidence and prevalence of KS in Eastern Africa. The
trend is consistent with the geographic variations of the HIV/AIDS epidemic. The key players include
Aphios Corporation, AstraZeneca Plc, Biogenomics Limited, and CytRx Corporation. Eli Lilly and Co.,